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Dear Editors,Fig. 1. Platelet aggregation determined in the whole blood by using a Multiplate
aggregometer in response to 6.5 μM ADP (A) and 3.2 μg/ml collagen (B). Tests were
performed in duplicate determinations. D1 indicates donors with high platelet reactivity;
D2 indicates donors with low platelet reactivity. The values are expressed in arbitrary
aggregation units (AU). For ADP: *p = 0.009; **p = 0.001; ***p = 0.0007. For collagen:
°p = 0.01; °°p = 0.003; °°°p = 0.001.Sildenaﬁl citrate is a potent vasodilating agent mainly used for erec-
tile dysfunction [1]. In the recent years, its use has also become more
popular among men without erectile dysfunction to enhance sexual
performance [2]. In addition, although not included in the WADA
(World Anti-Doping Agency) prohibited list, the increasing incidence
of its use among young athletes has drawn the attention of the anti-
doping authorities, who recognized its potential use associated with
steroid doping (http://www.realchampion.jp/assets/uploads/2013/03/
2010_ProhibitedList).
The drug is a selective inhibitor of phosphodiesterase type 5 (PDE-5)
that increases the action of nitric oxide by preventing the hydrolysis
of cyclic guanosine monophosphate. PDE-5 is located not only in the
corpus cavernosum (the main target of this drug) but also, in other
cells, including vessel cells and circulating cells [3].
Accordingly, evidence from clinical trials and experimental studies
suggested that sildenaﬁl could exert a plethora of pharmacological ben-
eﬁcial actions in different clinical matters [4]. For instance, in patients
with pulmonary arterial hypertension sildenaﬁl improves pulmonary
exercise capacity and quality of life by increasing the supply of blood
to the lungs. Furthermore, it has been shown that sildenaﬁl has a poten-
tial therapeutic efﬁcacy for disorders related to the central nervous sys-
tem. It exerts neuro-protective effects in multiple sclerosis and has a
signiﬁcant memory enhancing action [4]. However, unfortunately,
some adverse effect of the drug has also been reported. Acute myocar-
dial infarction, sudden cardiac death, symptomatic non-fatal ventricu-
lar arrhythmia, transient cerebral ischemic attacks, and hemorrhagic
stroke have been documented in patients engaging in sexual exertion
assisted with the use of sildenaﬁl [5,6].
Since platelet hyperactivity may cause thrombotic disorders [7]
whereas their hypo-aggregation can lead to hemorrhagic disorders
[8] in the present work we decided to evaluate the ex vivo effects of sil-
denaﬁl on platelet aggregation pattern in a small cohort of young and
healthy individuals (HD). Twenty non-smokers HDmen, aged between
20 and 40 years have been recruited at the Institute of Hematology,
University “La Sapienza” of Rome. The nature and purpose of the
study were explained to all participants who gave their informed con-
sent following the rules of good medical practice.http://dx.doi.org/10.1016/j.ijcme.2014.07.005
2214-7624/© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access articlWhole blood from HD, collected in tubes containing citrate, was
treated for 15 min with sildenaﬁl (Sigma) at concentrations of 20, 40
and 80 μM [9]. Platelet aggregation was evaluated in the whole blood
by using a Multiplate aggregometer and induced by adenosine diphos-
phate (ADP, 6.5 μM) and collagen (3.2 μg/ml). The main advantage of
whole blood aggregometry is that the evaluation of platelet function
can be performed under near physiological conditions, where platelets
can interact with other blood cells. For each donor the measurements
are performed in duplicate. A value of p b 0.05 was considered as
signiﬁcant.
As shown in Fig. 1, we found that sildenaﬁl reduced platelet aggrega-
tion induced by both ADP (Fig. 1A) and collagen (Fig. 1B) in a dose-
dependent manner. ADP is an important physiological platelet agonist
released from erythrocytes and platelets. Under physiologicale under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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values of 290–780 AU (arbitrary aggregation units). High platelet reac-
tivity to ADP (values higher than 780 AU) may be a risk factor for
thrombotic events, while very low platelet reactivity to ADP (values
less than 290 AU) may be a risk factor for hemorrhagic disorders [10].
Interestingly, in donors whose platelets after ADP administration
aggregate to a value near 290 AU, we found that sildenaﬁl reduced
aggregation at values below the physiological range (Fig. 1A). The
most signiﬁcant effect (p = 0.0007) was detectable at a concentration
of 80 μM. In donors whose platelets aggregate to values higher than
780 AU, sildenaﬁl reduced platelet aggregation maintaining these
values higher than the physiological range.
Collagen is another natural platelet agonist that, under physiological
conditions, triggers platelet aggregation via glycoprotein (GP) VI trans-
membrane receptor at mean values of 450–1150 AU. Interestingly, in
donors whose platelets aggregate at physiological values we found
that, at all concentrations used, sildenaﬁl signiﬁcantly reduced the ag-
gregation induced by collagen at values below the physiological range
(Fig. 1B).
This study “mimics” ex vivowhat could occur in the peripheral blood
after intake of sildenaﬁl. These data, although obtained in a small cohort
of young healthy subjects, seem in fact to indicate that sildenaﬁl can re-
duce platelet aggregation in a dose-dependent manner. On this basis
we could hypothesize that some beneﬁcial effect of sildenaﬁl, e.g. on
pulmonary hypertension, could stem on its antithrombotic activity.
Conversely, the abuse of this substance (e.g. for recreational use by
young healthy men and elite athletes) could represent a risk factor for
hemorrhagic disorders.
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